董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dipti Amin | 女 | Director | 59 | 10.35万美元 | 27.50 | 2023-07-20 |
| Anula Jayasuriya | 女 | Director | 66 | 10.35万美元 | 25.00 | 2023-07-20 |
| Don M. Bailey | 男 | Director | 77 | 13.91万美元 | 44.88 | 2023-07-20 |
| Neal C. Bradsher | 男 | Director | 57 | 11.85万美元 | 4987.86 | 2023-07-20 |
| Deborah Andrews | 女 | Director | 65 | 12.35万美元 | 24.56 | 2023-07-20 |
| Alfred D. Kingsley | 男 | Chairman of the Board | 80 | 5.37万美元 | 未持股 | 2023-07-20 |
| Brian M. Culley | 男 | Chief Executive Officer and Director | 52 | 211.12万美元 | 684.41 | 2023-07-20 |
| Michael H. Mulroy | 男 | Director | 56 | 16.10万美元 | 52.86 | 2023-07-20 |
| Angus C. Russell | 男 | Director | 67 | 12.10万美元 | 31.75 | 2023-07-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary S. Hogge | 男 | Senior Vice President of Clinical & Medical Affairs | 55 | 未披露 | 未持股 | 2023-07-20 |
| Jill A. Howe | 女 | Chief Financial Officer | 47 | 100.59万美元 | 95.88 | 2023-07-20 |
| George A. Samuel III | 男 | General Counsel and Corporate Secretary | 43 | 97.82万美元 | 177.43 | 2023-07-20 |
| Brian M. Culley | 男 | Chief Executive Officer and Director | 52 | 211.12万美元 | 684.41 | 2023-07-20 |
董事简历
中英对照 | 中文 | 英文- Dipti Amin
-
Dipti Amin目前担任Ixico PLC的非执行董事，她自2023年10月起担任该职位，并自2012年起担任IQVia的英国医疗重新验证评估师。Amin博士此前曾于2017年11月至2020年3月担任剑桥创新资本的非执行董事，于2017年8月至2021年底担任Maaya Associates Ltd.的董事，于2015年6月至2023年6月担任白金汉郡NHS信托的非执行董事，并于2018年9月至2024年8月担任赫特福德大学的非执行董事。1995年6月至2016年12月，Amin博士在生物制药开发和商业外包服务提供商Quintiles Transnational Corporation任职，在药物开发的所有阶段担任各种高级职务，最近于2010年4月至2016年12月担任高级副总裁兼首席合规官。阿明博士获得了伦敦大学盖斯和圣托马斯医院医学院的医学学位、皇家全科医学院的MRCGP、伦敦皇家内科医学院药物医学学院的FFPM、皇家妇产科医学院的DRCOG、伦敦皇家内科医学院的DGM和DCH，以及伦敦药剂师协会的DCPSA。
Dipti Amin,currently serves as a non-executive director of Ixico plc, a position she has held since October 2023, and as a UK Medical Revalidation Appraiser for Iqvia, a position she has held since 2012. Dr. Amin previously served as a non-executive director of Cambridge Innovation Capital from November 2017 to March 2020, as a director of Maaya Associates Ltd. from August 2017 through the end of 2021, as a non-executive director of Buckinghamshire NHS Trust, from June 2015 to June 2023, and as a non-executive director of the University of Hertfordshire from September 2018 to August 2024. From June 1995 to December 2016, Dr. Amin served at Quintiles Transnational Corporation, a provider of biopharmaceutical development and commercial outsourcing services, in various senior roles within all phases of drug development and most recently as Senior Vice President and Chief Compliance Officer from April 2010 to December 2016. Dr. Amin received her medical degree from Guys and St. Thomas's Hospitals Medical School of the University of London, her MRCGP from the Royal College of General Practitioners, her FFPM from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians London, her DRCOG from the Royal College of Obstetricians and Gynecologists, her DGM and DCH from the Royal College of Physicians, London and her DCPSA from the Society of Apothecaries of London. - Dipti Amin目前担任Ixico PLC的非执行董事，她自2023年10月起担任该职位，并自2012年起担任IQVia的英国医疗重新验证评估师。Amin博士此前曾于2017年11月至2020年3月担任剑桥创新资本的非执行董事，于2017年8月至2021年底担任Maaya Associates Ltd.的董事，于2015年6月至2023年6月担任白金汉郡NHS信托的非执行董事，并于2018年9月至2024年8月担任赫特福德大学的非执行董事。1995年6月至2016年12月，Amin博士在生物制药开发和商业外包服务提供商Quintiles Transnational Corporation任职，在药物开发的所有阶段担任各种高级职务，最近于2010年4月至2016年12月担任高级副总裁兼首席合规官。阿明博士获得了伦敦大学盖斯和圣托马斯医院医学院的医学学位、皇家全科医学院的MRCGP、伦敦皇家内科医学院药物医学学院的FFPM、皇家妇产科医学院的DRCOG、伦敦皇家内科医学院的DGM和DCH，以及伦敦药剂师协会的DCPSA。
- Dipti Amin,currently serves as a non-executive director of Ixico plc, a position she has held since October 2023, and as a UK Medical Revalidation Appraiser for Iqvia, a position she has held since 2012. Dr. Amin previously served as a non-executive director of Cambridge Innovation Capital from November 2017 to March 2020, as a director of Maaya Associates Ltd. from August 2017 through the end of 2021, as a non-executive director of Buckinghamshire NHS Trust, from June 2015 to June 2023, and as a non-executive director of the University of Hertfordshire from September 2018 to August 2024. From June 1995 to December 2016, Dr. Amin served at Quintiles Transnational Corporation, a provider of biopharmaceutical development and commercial outsourcing services, in various senior roles within all phases of drug development and most recently as Senior Vice President and Chief Compliance Officer from April 2010 to December 2016. Dr. Amin received her medical degree from Guys and St. Thomas's Hospitals Medical School of the University of London, her MRCGP from the Royal College of General Practitioners, her FFPM from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians London, her DRCOG from the Royal College of Obstetricians and Gynecologists, her DGM and DCH from the Royal College of Physicians, London and her DCPSA from the Society of Apothecaries of London.
- Anula Jayasuriya
-
Anula Jayasuriya是Kidron Capital的联合创始人兼董事总经理，Kidron Capital是一家专注于投资促进女性健康的风险基金，她自2022年1月以来一直担任该职位。她还是EXXclaim Capital的联合创始人和董事总经理，这是一家同样专注于女性健康创新的风险基金，她自2017年7月以来一直担任该职位。2006年，她与人共同创立了Evolvence印度生命科学基金，管理该基金至2017年7月。从2001年到2002年，Jayasuriya博士是帕洛阿尔托Skyline Ventures的合伙人，在此之前是旧金山的德国/美国风险投资公司TVM。她之前的职位包括1999年至2000年在Genomics Collaborative，Inc.担任业务发展副总裁，以及1994年至1998年在Hoffman-La Roche担任全球药物开发副总裁。Jayasuriya博士担任Jaguar Health, Inc.（JAGX）的董事。Jayasuriya博士以优异成绩获得哈佛大学学士学位、剑桥大学药理学硕士学位、哈佛医学院医学博士和博士学位（微生物学和分子遗传学）以及哈佛商学院的工商管理硕士学位。
Anula Jayasuriya,is the Co-Founder and Managing Director of Kidron Capital, a venture fund focused on investments in advancing women's health, a position she has held since January 2022. She is also the Co-Founder and Managing Director of EXXclaim Capital, a venture fund also focused on innovation in women's health, a position she has held since July 2017. In 2006, she co-founded the Evolvence India Life Science Fund, managing the fund until July of 2017. From 2001 to 2002, Dr. Jayasuriya was a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP, Business Development at Genomics Collaborative, Inc., from 1999 to 2000, and VP, Global Drug Development at Hoffman-La Roche from 1994 to 1998. Dr. Jayasuriya serves as a director of Jaguar Health, Inc. (JAGX). Dr. Jayasuriya received a B.A. from Harvard University summa cum laude, a M. Phil. in pharmacology from the University of Cambridge, an M.D. and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School and an M.B.A. with distinction from Harvard Business School. - Anula Jayasuriya是Kidron Capital的联合创始人兼董事总经理，Kidron Capital是一家专注于投资促进女性健康的风险基金，她自2022年1月以来一直担任该职位。她还是EXXclaim Capital的联合创始人和董事总经理，这是一家同样专注于女性健康创新的风险基金，她自2017年7月以来一直担任该职位。2006年，她与人共同创立了Evolvence印度生命科学基金，管理该基金至2017年7月。从2001年到2002年，Jayasuriya博士是帕洛阿尔托Skyline Ventures的合伙人，在此之前是旧金山的德国/美国风险投资公司TVM。她之前的职位包括1999年至2000年在Genomics Collaborative，Inc.担任业务发展副总裁，以及1994年至1998年在Hoffman-La Roche担任全球药物开发副总裁。Jayasuriya博士担任Jaguar Health, Inc.（JAGX）的董事。Jayasuriya博士以优异成绩获得哈佛大学学士学位、剑桥大学药理学硕士学位、哈佛医学院医学博士和博士学位（微生物学和分子遗传学）以及哈佛商学院的工商管理硕士学位。
- Anula Jayasuriya,is the Co-Founder and Managing Director of Kidron Capital, a venture fund focused on investments in advancing women's health, a position she has held since January 2022. She is also the Co-Founder and Managing Director of EXXclaim Capital, a venture fund also focused on innovation in women's health, a position she has held since July 2017. In 2006, she co-founded the Evolvence India Life Science Fund, managing the fund until July of 2017. From 2001 to 2002, Dr. Jayasuriya was a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP, Business Development at Genomics Collaborative, Inc., from 1999 to 2000, and VP, Global Drug Development at Hoffman-La Roche from 1994 to 1998. Dr. Jayasuriya serves as a director of Jaguar Health, Inc. (JAGX). Dr. Jayasuriya received a B.A. from Harvard University summa cum laude, a M. Phil. in pharmacology from the University of Cambridge, an M.D. and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School and an M.B.A. with distinction from Harvard Business School.
- Don M. Bailey
-
Don M. Bailey，他于2006年加入Asterias Biotherapeutics, Inc. 的董事会，担任总裁兼首席执行官。 他于2007年5月被任命为Asterias Biotherapeutics, Inc. 的临时总裁。他在2007年11月被任命为总裁兼首席执行官。他目前是STAAR Surgical Company（采用专有技术的微创眼科产品的开发、制造、销售的领先者）的董事会成员。他曾担任Comarco公司的董事会主席（从1998年到2007年），以及Comarco公司的首席执行官（从1991年到2000年）。他曾担任STAAR公司的董事会主席（从2005年4月到2014年1月）。他持有the Drexel Institute of Technology的机械工程学士学位、南加利福尼亚大学（the University of Southern California）的作业研究硕士学位，以及Pepperdine University的工商管理硕士学位。
Don M. Bailey,previously served as a director and Chairman of Asterias Biotherapeutics, Inc. (AST) from February 2016 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. Mr. Bailey served as President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. (QCOR), a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders, from 2007 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He was also a director of Mallinckrodt plc from August 2014 to March 2016, and during this time he was the Chairman of its portfolio committee. He initially joined the Questcor board of directors in 2006 as an independent director and Chairman of its audit committee. From August 2016 to November 2017, Mr. Bailey served as a director of OncoCyte Corporation (OCX). From June 2015 until its acquisition by Acorda Therapeutics, Inc. (ACOR) in May 2016, Mr. Bailey was also an independent director and chairman of the audit committee of Biotie Therapeutics Corp. (BITI), a clinical-stage pharmaceutical company headquartered in Turku, Finland. Mr. Bailey was an independent director and the non-executive chairman of the board of directors of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from 2005 until 2014. Mr. Bailey served on its audit committee and was chair of its nominating and corporate governance committee. Mr. Bailey was the chairman of the board of directors of Comarco, Inc. (CMRO), a defense services company transformed into a wireless communication products company, from 1998 until 2007, where he served as Chief Executive Officer from 1991 until 2000. Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operations research from the University of Southern California and an M.B.A. from Pepperdine University. Mr. Bailey has also served as a board member on several non-profit and academic enterprises. Mr. Bailey is a founding board member of the University of California Irvine's (UCI) Applied Innovation Institute. - Don M. Bailey，他于2006年加入Asterias Biotherapeutics, Inc. 的董事会，担任总裁兼首席执行官。 他于2007年5月被任命为Asterias Biotherapeutics, Inc. 的临时总裁。他在2007年11月被任命为总裁兼首席执行官。他目前是STAAR Surgical Company（采用专有技术的微创眼科产品的开发、制造、销售的领先者）的董事会成员。他曾担任Comarco公司的董事会主席（从1998年到2007年），以及Comarco公司的首席执行官（从1991年到2000年）。他曾担任STAAR公司的董事会主席（从2005年4月到2014年1月）。他持有the Drexel Institute of Technology的机械工程学士学位、南加利福尼亚大学（the University of Southern California）的作业研究硕士学位，以及Pepperdine University的工商管理硕士学位。
- Don M. Bailey,previously served as a director and Chairman of Asterias Biotherapeutics, Inc. (AST) from February 2016 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. Mr. Bailey served as President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. (QCOR), a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders, from 2007 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He was also a director of Mallinckrodt plc from August 2014 to March 2016, and during this time he was the Chairman of its portfolio committee. He initially joined the Questcor board of directors in 2006 as an independent director and Chairman of its audit committee. From August 2016 to November 2017, Mr. Bailey served as a director of OncoCyte Corporation (OCX). From June 2015 until its acquisition by Acorda Therapeutics, Inc. (ACOR) in May 2016, Mr. Bailey was also an independent director and chairman of the audit committee of Biotie Therapeutics Corp. (BITI), a clinical-stage pharmaceutical company headquartered in Turku, Finland. Mr. Bailey was an independent director and the non-executive chairman of the board of directors of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from 2005 until 2014. Mr. Bailey served on its audit committee and was chair of its nominating and corporate governance committee. Mr. Bailey was the chairman of the board of directors of Comarco, Inc. (CMRO), a defense services company transformed into a wireless communication products company, from 1998 until 2007, where he served as Chief Executive Officer from 1991 until 2000. Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operations research from the University of Southern California and an M.B.A. from Pepperdine University. Mr. Bailey has also served as a board member on several non-profit and academic enterprises. Mr. Bailey is a founding board member of the University of California Irvine's (UCI) Applied Innovation Institute.
- Neal C. Bradsher
-
Neal C. Bradsher，他是一位注册金融分析师，加入了董事会于2009年7月。自2002年以来他一直是乐活资本公司（一家私人投资公司）的总裁。他持有耶鲁大学的经济学学士学位和是一位注册金融分析师。他亦为QUESTCOR制药公司（一家生物制药公司，侧重于有严重，难以治疗自身免疫性疾病和炎症性疾病的患者的治疗）的董事。
Neal C. Bradsher,has been President of Broadwood Capital, Inc., a private investment firm, since 2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher has served as a director of STAAR Surgical Company since January 2026 and is currently Chair of its Board of Directors. He was a director of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired in 2014.He has worked with several health care companies to improve their management and governance. Entities that Mr. Bradsher controls have invested in many of Lineage's financing transactions. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P., currently largest shareholder. - Neal C. Bradsher，他是一位注册金融分析师，加入了董事会于2009年7月。自2002年以来他一直是乐活资本公司（一家私人投资公司）的总裁。他持有耶鲁大学的经济学学士学位和是一位注册金融分析师。他亦为QUESTCOR制药公司（一家生物制药公司，侧重于有严重，难以治疗自身免疫性疾病和炎症性疾病的患者的治疗）的董事。
- Neal C. Bradsher,has been President of Broadwood Capital, Inc., a private investment firm, since 2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher has served as a director of STAAR Surgical Company since January 2026 and is currently Chair of its Board of Directors. He was a director of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired in 2014.He has worked with several health care companies to improve their management and governance. Entities that Mr. Bradsher controls have invested in many of Lineage's financing transactions. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P., currently largest shareholder.
- Deborah Andrews
-
Deborah Andrews自2013年9月起任一家上市的生物技术公司BioTime, Inc.的首席会计师，自2014年4月起任董事会和审计委员会成员，该公司专注于再生药物的新兴领域。在这之前，2005年8月至2013年9月Andrews女士曾是STAAR的副总裁兼首席财务官，她从1995年开始就在STAAR工作，2005年4月至2005年8月任STAAR财务总监，2001年至2005年任全球财务总监，1999年至2001年任STAAR Surgical AG Switzerland财务副总裁，1995年至1999年任财务总监助理。1994年至1995年她是电子元件制造商Bourns, Inc.的内部审计员，1991年至1994年是KPMG Peat Marwick的一名审计员。Andrews女士获得了圣贝纳迪诺的California State University的会计学学士学位。
Deborah Andrews was appointed Interim Co-CEO, to serve alongside Mr. Foust, while the Company conducts a global search for its next CEO. Ms. Andrews also serves as the Company's Chief Financial Officer. Ms. Andrews joined STAAR in March 2025 as Interim Chief Financial Officer, and was appointed Chief Financial Officer in June 2025. In this role, Ms. Andrews oversees STAAR's finance, accounting, and internal audit functions, as well as information technology. She most recently served as the Company's Chief Financial Officer, from September 2017 until her retirement in June 2020, after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as the Company's Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Since April 2014, Ms. Andrews has served on the Board of Directors of Lineage Cell Therapeutics, a clinical stage biotechnology company focused in the field of regenerative medicine. She currently serves as its Audit Committee Chair and has previously served as its Compensation Committee Chair. Ms. Andrews spent three years from 1991 to 1994 as an accountant for KPMG.Ms. Andrews holds a B.S. degree in accounting from California State University at San Bernardino. - Deborah Andrews自2013年9月起任一家上市的生物技术公司BioTime, Inc.的首席会计师，自2014年4月起任董事会和审计委员会成员，该公司专注于再生药物的新兴领域。在这之前，2005年8月至2013年9月Andrews女士曾是STAAR的副总裁兼首席财务官，她从1995年开始就在STAAR工作，2005年4月至2005年8月任STAAR财务总监，2001年至2005年任全球财务总监，1999年至2001年任STAAR Surgical AG Switzerland财务副总裁，1995年至1999年任财务总监助理。1994年至1995年她是电子元件制造商Bourns, Inc.的内部审计员，1991年至1994年是KPMG Peat Marwick的一名审计员。Andrews女士获得了圣贝纳迪诺的California State University的会计学学士学位。
- Deborah Andrews was appointed Interim Co-CEO, to serve alongside Mr. Foust, while the Company conducts a global search for its next CEO. Ms. Andrews also serves as the Company's Chief Financial Officer. Ms. Andrews joined STAAR in March 2025 as Interim Chief Financial Officer, and was appointed Chief Financial Officer in June 2025. In this role, Ms. Andrews oversees STAAR's finance, accounting, and internal audit functions, as well as information technology. She most recently served as the Company's Chief Financial Officer, from September 2017 until her retirement in June 2020, after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as the Company's Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Since April 2014, Ms. Andrews has served on the Board of Directors of Lineage Cell Therapeutics, a clinical stage biotechnology company focused in the field of regenerative medicine. She currently serves as its Audit Committee Chair and has previously served as its Compensation Committee Chair. Ms. Andrews spent three years from 1991 to 1994 as an accountant for KPMG.Ms. Andrews holds a B.S. degree in accounting from California State University at San Bernardino.
- Alfred D. Kingsley
-
Alfred D. Kingsley，他加入董事会，成为董事会主席于2009年7月。他是五家公司附属公司的执行董事长。自1993年以来，他一直Greenway Partners有限公司（一家私人投资公司）的普通合伙人，Greenbelt公司（企业咨询公司）的总裁。他担任公司的金融顾问从1998年直到2009年6月30日。他是伊坎公司的高级副总裁超过25年。他是公司附属公司海星生物治疗公司的董事。他持有宾夕法尼亚大学沃顿商学院经济学学士学位，和纽约大学法学院税务法学博士学位和法学硕士学位。
Alfred D. Kingsley,has been Chairman of the Board since July 2009. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt served as Lineage Cell Therapeutics, Inc. financial advisor from 1998 until 2009. Mr. Kingsley also serves as a director of OncoCyte Corporation (OCX), a clinical-stage diagnostics company focused on novel, non-invasive blood-based tests for the early detection of cancer. From January 2017 to October 2018, Mr. Kingsley served as Executive Chairman of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Kingsley also served as a director of Asterias Biotherapeutics, Inc. (AST) from 2012 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a B.S. degree in economics from the Wharton School of the University of Pennsylvania and a J.D. degree and LLM in taxation from New York University Law School. - Alfred D. Kingsley，他加入董事会，成为董事会主席于2009年7月。他是五家公司附属公司的执行董事长。自1993年以来，他一直Greenway Partners有限公司（一家私人投资公司）的普通合伙人，Greenbelt公司（企业咨询公司）的总裁。他担任公司的金融顾问从1998年直到2009年6月30日。他是伊坎公司的高级副总裁超过25年。他是公司附属公司海星生物治疗公司的董事。他持有宾夕法尼亚大学沃顿商学院经济学学士学位，和纽约大学法学院税务法学博士学位和法学硕士学位。
- Alfred D. Kingsley,has been Chairman of the Board since July 2009. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt served as Lineage Cell Therapeutics, Inc. financial advisor from 1998 until 2009. Mr. Kingsley also serves as a director of OncoCyte Corporation (OCX), a clinical-stage diagnostics company focused on novel, non-invasive blood-based tests for the early detection of cancer. From January 2017 to October 2018, Mr. Kingsley served as Executive Chairman of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Kingsley also served as a director of Asterias Biotherapeutics, Inc. (AST) from 2012 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a B.S. degree in economics from the Wharton School of the University of Pennsylvania and a J.D. degree and LLM in taxation from New York University Law School.
- Brian M. Culley
-
Brian M. Culley， 自2010年2月以来，担任本公司的首席执行官。自2011年12月以来，是本公司董事会的成员。自2009年2月以来，是本公司的行政主管。此前，他曾于2007年1月-2010年2月期间，担任本公司的商务总监和高级副总裁；2006年2月-2007年1月期间，曾担任本公司的商业开发高级副总裁；以及2004年12月-2006年2月期间，曾担任本公司的商业开发副总裁。2002-2004年期间，曾在San Diego市的iTherx股份有限公司（原为Immusol股份有限公司）管理所有的战略合作和许可协议，最近的职位是商业开发和营销总监。1999-2000年期间，曾是San Diego市加州大学（University of California）技术转让&和知识产权服务系的许可和营销准学士；1996-1999年期间，曾是Neurocrine Biosciences股份有限公司的一位研究助理。他拥有着超过20年的生命科学行业经验。他是在Boston大学获得生物学学士学位、在Santa Barbara市加州大学（University of California）获得生物化学硕士学位，以及在Cornell大学Johnson商学院获得工商管理学硕士学位的。
Brian M. Culley,joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast's merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast's Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast's Senior Vice President, Business Development, and from 2004 to 2006 as Mast's Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022. Mr. Culley has more than 30 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. - Brian M. Culley， 自2010年2月以来，担任本公司的首席执行官。自2011年12月以来，是本公司董事会的成员。自2009年2月以来，是本公司的行政主管。此前，他曾于2007年1月-2010年2月期间，担任本公司的商务总监和高级副总裁；2006年2月-2007年1月期间，曾担任本公司的商业开发高级副总裁；以及2004年12月-2006年2月期间，曾担任本公司的商业开发副总裁。2002-2004年期间，曾在San Diego市的iTherx股份有限公司（原为Immusol股份有限公司）管理所有的战略合作和许可协议，最近的职位是商业开发和营销总监。1999-2000年期间，曾是San Diego市加州大学（University of California）技术转让&和知识产权服务系的许可和营销准学士；1996-1999年期间，曾是Neurocrine Biosciences股份有限公司的一位研究助理。他拥有着超过20年的生命科学行业经验。他是在Boston大学获得生物学学士学位、在Santa Barbara市加州大学（University of California）获得生物化学硕士学位，以及在Cornell大学Johnson商学院获得工商管理学硕士学位的。
- Brian M. Culley,joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast's merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast's Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast's Senior Vice President, Business Development, and from 2004 to 2006 as Mast's Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022. Mr. Culley has more than 30 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.
- Michael H. Mulroy
-
Michael H. Mulroy，自2017年6月起担任Asterias Biotherapeutics, Inc.（AST）的首席执行官和董事会成员，直至Lineage Cell Therapeutics，Inc.于2019年3月收购Asterias。2020年4月，Mulroy先生兼职加入Magtrol Inc.，这是一家领先的电机测试设备和迟滞制动器和离合器制造商，他还担任该公司的董事会成员。在加入Asterias之前，Mulroy先生曾担任CamberView Partners，LLC（现为PJT Partners Inc.的一部分）的高级顾问，CamberView Partners，LLC在投资者参与和复杂的公司治理问题方面为公司提供协助。在2014年出售之前，Mulroy先生曾担任Questcor Pharmaceuticals, Inc.（QCOR）的执行副总裁、战略事务和总法律顾问兼公司秘书。Mulroy先生于2011年加入Questcor，担任首席财务官、总法律顾问和公司秘书。2017年1月至2019年7月，Mulroy先生担任AgeX Terapeutics，Inc.（AGE）的董事会成员，AgeX Therapeutics，Inc.是一家生物技术公司，专注于针对人类衰老的新型疗法的开发和商业化。Mulroy先生获得了加州大学洛杉矶分校的法学博士学位和芝加哥大学的经济学学士学位。
Michael H. Mulroy,was appointed Chairman of the Board in April 2024. Mr. Mulroy served as the Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc. (AST) from June 2017 until acquisition of Asterias in March 2019. In April 2020, Mr. Mulroy joined Magtrol Inc., a leading manufacturer of motor test equipment and hysteresis brakes and clutches, on a part-time basis, where he also serves on its board of directors. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT Partners Inc.), which assists companies in connection with investor engagement and complex corporate governance issues. Prior to its sale in 2014, Mr. Mulroy served as Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor Pharmaceuticals, Inc. (QCOR). Mr. Mulroy joined Questcor in 2011 as Chief Financial Officer, General Counsel and Corporate Secretary. From January 2017 to July 2019, Mr. Mulroy served as a member of the board of directors of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. degree in economics from the University of Chicago. - Michael H. Mulroy，自2017年6月起担任Asterias Biotherapeutics, Inc.（AST）的首席执行官和董事会成员，直至Lineage Cell Therapeutics，Inc.于2019年3月收购Asterias。2020年4月，Mulroy先生兼职加入Magtrol Inc.，这是一家领先的电机测试设备和迟滞制动器和离合器制造商，他还担任该公司的董事会成员。在加入Asterias之前，Mulroy先生曾担任CamberView Partners，LLC（现为PJT Partners Inc.的一部分）的高级顾问，CamberView Partners，LLC在投资者参与和复杂的公司治理问题方面为公司提供协助。在2014年出售之前，Mulroy先生曾担任Questcor Pharmaceuticals, Inc.（QCOR）的执行副总裁、战略事务和总法律顾问兼公司秘书。Mulroy先生于2011年加入Questcor，担任首席财务官、总法律顾问和公司秘书。2017年1月至2019年7月，Mulroy先生担任AgeX Terapeutics，Inc.（AGE）的董事会成员，AgeX Therapeutics，Inc.是一家生物技术公司，专注于针对人类衰老的新型疗法的开发和商业化。Mulroy先生获得了加州大学洛杉矶分校的法学博士学位和芝加哥大学的经济学学士学位。
- Michael H. Mulroy,was appointed Chairman of the Board in April 2024. Mr. Mulroy served as the Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc. (AST) from June 2017 until acquisition of Asterias in March 2019. In April 2020, Mr. Mulroy joined Magtrol Inc., a leading manufacturer of motor test equipment and hysteresis brakes and clutches, on a part-time basis, where he also serves on its board of directors. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT Partners Inc.), which assists companies in connection with investor engagement and complex corporate governance issues. Prior to its sale in 2014, Mr. Mulroy served as Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor Pharmaceuticals, Inc. (QCOR). Mr. Mulroy joined Questcor in 2011 as Chief Financial Officer, General Counsel and Corporate Secretary. From January 2017 to July 2019, Mr. Mulroy served as a member of the board of directors of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. degree in economics from the University of Chicago.
- Angus C. Russell
-
Angus C. Russell自2011年10月起担任董事会成员。2008年6月至2013年4月其退休，他担任生物制药公司Shire plc（“Shire”）的首席执行官，并且曾是其董事会1999年至2013年的成员。1999年12月至2008年6月他担任Shire的首席财务官。他是一位City of London Investment Trust plc的前非执行董事。他是一名特许会计师以及Association of Corporate Treasurers的一位会员。
Angus C. Russell,served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as its Principal Accounting Officer and Executive Vice President of Global Finance. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca plc (AZN). Mr. Russell also serves as a member of the Board of Directors of Structure Therapeutics, Inc., a position he has held since August 2024. Mr. Russell served as Chairman of the Board of Directors of Revance Therapeutics, Inc. (RVNC) from March 2014 until it was acquired by Crown Laboratories, Inc. in February 2025. Mr. Russell served as a director of Shire plc from December 1999 to April 2013, as a director of Mallinckrodt plc (MNK) from August 2014 to June 2022, and as a director of Therapeutics MD, Inc. (TXMD) from March 2015 to December 2022. Mr. Russell holds an honorary Doctor of Business Administration from Coventry University; U.K. - Angus C. Russell自2011年10月起担任董事会成员。2008年6月至2013年4月其退休，他担任生物制药公司Shire plc（“Shire”）的首席执行官，并且曾是其董事会1999年至2013年的成员。1999年12月至2008年6月他担任Shire的首席财务官。他是一位City of London Investment Trust plc的前非执行董事。他是一名特许会计师以及Association of Corporate Treasurers的一位会员。
- Angus C. Russell,served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as its Principal Accounting Officer and Executive Vice President of Global Finance. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca plc (AZN). Mr. Russell also serves as a member of the Board of Directors of Structure Therapeutics, Inc., a position he has held since August 2024. Mr. Russell served as Chairman of the Board of Directors of Revance Therapeutics, Inc. (RVNC) from March 2014 until it was acquired by Crown Laboratories, Inc. in February 2025. Mr. Russell served as a director of Shire plc from December 1999 to April 2013, as a director of Mallinckrodt plc (MNK) from August 2014 to June 2022, and as a director of Therapeutics MD, Inc. (TXMD) from March 2015 to December 2022. Mr. Russell holds an honorary Doctor of Business Administration from Coventry University; U.K.
高管简历
中英对照 | 中文 | 英文- Gary S. Hogge
Gary S.霍格于2018年2月加入EAGE，担任临床和医疗事务高级副总裁。Hogge博士拥有20年的经验，在广泛的治疗领域开发和支持多个产品的商业化。Hogge博士在临床开发和医疗事务的多个治疗领域担任着各种职责递增的角色。此前，霍格博士是QuestcorPharmaceuticals，Inc.医疗事务Vice President。在此之前，QCOR在Elan Pharmaceuticals的临床开发和医疗事务中担任多个领导职务，包括在Crohn&8217；s病和多发性硬化症的Tysabri&174；（Natalizumab）的全球临床开发中的各种职责，以及建立和领导医疗事务职能。他曾担任Tysabri公司的批准和上市后的医疗董事。在取得这些成就之前，他曾在Maxim Pharmaceuticals的Ceplene®；（盐酸组胺）和辉瑞公司的免疫学研究与开发小组从事临床开发工作。Hogge博士在科罗拉多州立大学（Colorado State University）获得B.S.学位和D.V.M.，在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得M.S.和博士学位，是澳大利亚布里斯班昆士兰医学研究所（QIMR）的客座科学家。
Gary S. Hogge,joined Lineage as Senior Vice President of Clinical and Medical Affairs in February 2018. Dr. Hogge has more than 20 years of experience developing and supporting the commercialization of a number of products over a broad range of therapeutic areas. Dr. Hogge has held a variety of roles of increasing responsibility across multiple therapeutic areas in both clinical development and medical affairs. Previously Dr. Hogge was the Vice President of Medical Affairs at Questcor Pharmaceuticals, Inc. (QCOR) and before that held multiple leadership roles in both clinical development and medical affairs at Elan Pharmaceuticals including various responsibilities in the global clinical development of Tysabri (natalizumab) in Crohn's disease and multiple sclerosis, and for building and leading the medical affairs function. He served as medical director following the approval and launch of Tysabri. Prior to those accomplishments, he worked in clinical development for Ceplene (histamine dihydrochloride) at Maxim Pharmaceuticals and in the immunology research and development group at Pfizer. Dr. Hogge obtained his B.S. degree and D.V.M. from Colorado State University, his M.S. and Ph.D. from the University of Wisconsin-Madison and was a visiting scientist at the Queensland Institute of Medical Research (QIMR) in Brisbane, Australia.- Gary S.霍格于2018年2月加入EAGE，担任临床和医疗事务高级副总裁。Hogge博士拥有20年的经验，在广泛的治疗领域开发和支持多个产品的商业化。Hogge博士在临床开发和医疗事务的多个治疗领域担任着各种职责递增的角色。此前，霍格博士是QuestcorPharmaceuticals，Inc.医疗事务Vice President。在此之前，QCOR在Elan Pharmaceuticals的临床开发和医疗事务中担任多个领导职务，包括在Crohn&8217；s病和多发性硬化症的Tysabri&174；（Natalizumab）的全球临床开发中的各种职责，以及建立和领导医疗事务职能。他曾担任Tysabri公司的批准和上市后的医疗董事。在取得这些成就之前，他曾在Maxim Pharmaceuticals的Ceplene®；（盐酸组胺）和辉瑞公司的免疫学研究与开发小组从事临床开发工作。Hogge博士在科罗拉多州立大学（Colorado State University）获得B.S.学位和D.V.M.，在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得M.S.和博士学位，是澳大利亚布里斯班昆士兰医学研究所（QIMR）的客座科学家。
- Gary S. Hogge,joined Lineage as Senior Vice President of Clinical and Medical Affairs in February 2018. Dr. Hogge has more than 20 years of experience developing and supporting the commercialization of a number of products over a broad range of therapeutic areas. Dr. Hogge has held a variety of roles of increasing responsibility across multiple therapeutic areas in both clinical development and medical affairs. Previously Dr. Hogge was the Vice President of Medical Affairs at Questcor Pharmaceuticals, Inc. (QCOR) and before that held multiple leadership roles in both clinical development and medical affairs at Elan Pharmaceuticals including various responsibilities in the global clinical development of Tysabri (natalizumab) in Crohn's disease and multiple sclerosis, and for building and leading the medical affairs function. He served as medical director following the approval and launch of Tysabri. Prior to those accomplishments, he worked in clinical development for Ceplene (histamine dihydrochloride) at Maxim Pharmaceuticals and in the immunology research and development group at Pfizer. Dr. Hogge obtained his B.S. degree and D.V.M. from Colorado State University, his M.S. and Ph.D. from the University of Wisconsin-Madison and was a visiting scientist at the Queensland Institute of Medical Research (QIMR) in Brisbane, Australia.
- Jill A. Howe
Jill A. Howe，2022年11月加入Lineage，担任首席财务官。在加入Lineage之前，Howe女士最近在生物技术公司DTX Pharma，Inc.担任首席财务官，该职位于2021年6月至2022年7月期间担任。在加入DTX Pharma之前，2018年1月至2021年6月，Howe女士曾担任临床阶段生物制药公司Gossamer Bio, Inc.（纳斯达克：GOSS）的财务副总裁兼财务主管。在加入Gossamer Bio之前，她于2016年3月至2017年12月担任生物制药公司Amplyx Pharmaceuticals，Inc.的财务总监兼财务总监。她此前曾在生物技术公司Receptos, Inc.和专业制药公司Somaxon制药担任过财务总监和财务总监等职务。自2021年10月以来，Howe女士一直担任Codagenix Inc.的董事会成员。Howe女士获得了圣地亚哥州立大学的会计学学士学位。
Jill A. Howe,joined Lineage as Chief Financial Officer in November 2022. Before joining Lineage, Ms. Howe most recently served as the Chief Financial Officer of DTx Pharma, Inc., a biotechnology company, a position she held from June 2021 through July 2022. Prior to joining DTx Pharma, from January 2018 to June 2021, Ms. Howe served as Vice President of Finance and Treasurer for Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company. Prior to Gossamer Bio, she served as Controller & Director of Finance of Amplyx Pharmaceuticals, Inc., a biopharmaceutical company, from March 2016 to December 2017. She previously held positions, including as Controller and Director of Finance, at Receptos, Inc., a biotechnology company, and at Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company. Since October 2021, Ms. Howe has served on the board of directors of Codagenix Inc. Ms. Howe earned a B.S. in Accountancy from San Diego State University.- Jill A. Howe，2022年11月加入Lineage，担任首席财务官。在加入Lineage之前，Howe女士最近在生物技术公司DTX Pharma，Inc.担任首席财务官，该职位于2021年6月至2022年7月期间担任。在加入DTX Pharma之前，2018年1月至2021年6月，Howe女士曾担任临床阶段生物制药公司Gossamer Bio, Inc.（纳斯达克：GOSS）的财务副总裁兼财务主管。在加入Gossamer Bio之前，她于2016年3月至2017年12月担任生物制药公司Amplyx Pharmaceuticals，Inc.的财务总监兼财务总监。她此前曾在生物技术公司Receptos, Inc.和专业制药公司Somaxon制药担任过财务总监和财务总监等职务。自2021年10月以来，Howe女士一直担任Codagenix Inc.的董事会成员。Howe女士获得了圣地亚哥州立大学的会计学学士学位。
- Jill A. Howe,joined Lineage as Chief Financial Officer in November 2022. Before joining Lineage, Ms. Howe most recently served as the Chief Financial Officer of DTx Pharma, Inc., a biotechnology company, a position she held from June 2021 through July 2022. Prior to joining DTx Pharma, from January 2018 to June 2021, Ms. Howe served as Vice President of Finance and Treasurer for Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company. Prior to Gossamer Bio, she served as Controller & Director of Finance of Amplyx Pharmaceuticals, Inc., a biopharmaceutical company, from March 2016 to December 2017. She previously held positions, including as Controller and Director of Finance, at Receptos, Inc., a biotechnology company, and at Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company. Since October 2021, Ms. Howe has served on the board of directors of Codagenix Inc. Ms. Howe earned a B.S. in Accountancy from San Diego State University.
- George A. Samuel III
George A. Samuel III，于2021年9月加入Lineage，担任总法律顾问和公司秘书。在加入Lineage之前，Samuel先生最近担任Lytx，Inc.的董事、高级法律顾问，负责管理一家国际视频远程信息SaaS公司的商业法律运营，他于2020年1月至2021年8月担任该职位。在此之前，Samuel先生曾担任Cardiff Oncology, Inc.（前身为Trovagene，Inc.）的副总裁、总法律顾问和公司秘书，该公司是一家临床阶段的生物技术公司，专注于开发肿瘤学治疗方法。在他的职业生涯中，他为战略、业务发展和运营决策提供咨询；监督融资工作、监管合规以及SEC报告；并管理知识产权，包括技术转让和许可。Samuel先生还曾在Cooley LLP、DLA Piper LLP和Winston & Strawn LLP从事公司法业务，在各种商业交易中担任上市公司和私营公司的外部法律顾问。Samuel先生在哥伦比亚大学法学院获得法学博士学位，在塔夫茨大学获得哲学学士学位，并且是加利福尼亚州和纽约州律师协会的成员。
George A. Samuel III,joined Lineage as General Counsel and Corporate Secretary in September 2021. Prior to joining Lineage, Mr. Samuel most recently served as Director, Senior Counsel for Lytx, Inc., where he managed the commercial legal operations for an international video telematics SaaS company, a position he held from January 2020 to August 2021. Prior to that, Mr. Samuel served as VP, General Counsel and Corporate Secretary for Cardiff Oncology, Inc. (formerly known as Trovagene, Inc.), a clinical-stage biotechnology company focused on developing treatments in oncology. In his career, he advised on strategic, business development and operational decisions; oversaw capital raising efforts, regulatory compliance as well as SEC reporting; and managed intellectual property, including technology transfer and licensing. Mr. Samuel has also practiced corporate law at Cooley LLP, DLA Piper LLP, and Winston & Strawn LLP, where he served as outside counsel to public and private companies in a variety of commercial transactions. Mr. Samuel received a J.D. from Columbia University School of Law, and a B.A. in Philosophy from Tufts University and is a member of the State Bar of California and New York.- George A. Samuel III，于2021年9月加入Lineage，担任总法律顾问和公司秘书。在加入Lineage之前，Samuel先生最近担任Lytx，Inc.的董事、高级法律顾问，负责管理一家国际视频远程信息SaaS公司的商业法律运营，他于2020年1月至2021年8月担任该职位。在此之前，Samuel先生曾担任Cardiff Oncology, Inc.（前身为Trovagene，Inc.）的副总裁、总法律顾问和公司秘书，该公司是一家临床阶段的生物技术公司，专注于开发肿瘤学治疗方法。在他的职业生涯中，他为战略、业务发展和运营决策提供咨询；监督融资工作、监管合规以及SEC报告；并管理知识产权，包括技术转让和许可。Samuel先生还曾在Cooley LLP、DLA Piper LLP和Winston & Strawn LLP从事公司法业务，在各种商业交易中担任上市公司和私营公司的外部法律顾问。Samuel先生在哥伦比亚大学法学院获得法学博士学位，在塔夫茨大学获得哲学学士学位，并且是加利福尼亚州和纽约州律师协会的成员。
- George A. Samuel III,joined Lineage as General Counsel and Corporate Secretary in September 2021. Prior to joining Lineage, Mr. Samuel most recently served as Director, Senior Counsel for Lytx, Inc., where he managed the commercial legal operations for an international video telematics SaaS company, a position he held from January 2020 to August 2021. Prior to that, Mr. Samuel served as VP, General Counsel and Corporate Secretary for Cardiff Oncology, Inc. (formerly known as Trovagene, Inc.), a clinical-stage biotechnology company focused on developing treatments in oncology. In his career, he advised on strategic, business development and operational decisions; oversaw capital raising efforts, regulatory compliance as well as SEC reporting; and managed intellectual property, including technology transfer and licensing. Mr. Samuel has also practiced corporate law at Cooley LLP, DLA Piper LLP, and Winston & Strawn LLP, where he served as outside counsel to public and private companies in a variety of commercial transactions. Mr. Samuel received a J.D. from Columbia University School of Law, and a B.A. in Philosophy from Tufts University and is a member of the State Bar of California and New York.
- Brian M. Culley
Brian M. Culley， 自2010年2月以来，担任本公司的首席执行官。自2011年12月以来，是本公司董事会的成员。自2009年2月以来，是本公司的行政主管。此前，他曾于2007年1月-2010年2月期间，担任本公司的商务总监和高级副总裁；2006年2月-2007年1月期间，曾担任本公司的商业开发高级副总裁；以及2004年12月-2006年2月期间，曾担任本公司的商业开发副总裁。2002-2004年期间，曾在San Diego市的iTherx股份有限公司（原为Immusol股份有限公司）管理所有的战略合作和许可协议，最近的职位是商业开发和营销总监。1999-2000年期间，曾是San Diego市加州大学（University of California）技术转让&和知识产权服务系的许可和营销准学士；1996-1999年期间，曾是Neurocrine Biosciences股份有限公司的一位研究助理。他拥有着超过20年的生命科学行业经验。他是在Boston大学获得生物学学士学位、在Santa Barbara市加州大学（University of California）获得生物化学硕士学位，以及在Cornell大学Johnson商学院获得工商管理学硕士学位的。
Brian M. Culley,joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast's merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast's Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast's Senior Vice President, Business Development, and from 2004 to 2006 as Mast's Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022. Mr. Culley has more than 30 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.- Brian M. Culley， 自2010年2月以来，担任本公司的首席执行官。自2011年12月以来，是本公司董事会的成员。自2009年2月以来，是本公司的行政主管。此前，他曾于2007年1月-2010年2月期间，担任本公司的商务总监和高级副总裁；2006年2月-2007年1月期间，曾担任本公司的商业开发高级副总裁；以及2004年12月-2006年2月期间，曾担任本公司的商业开发副总裁。2002-2004年期间，曾在San Diego市的iTherx股份有限公司（原为Immusol股份有限公司）管理所有的战略合作和许可协议，最近的职位是商业开发和营销总监。1999-2000年期间，曾是San Diego市加州大学（University of California）技术转让&和知识产权服务系的许可和营销准学士；1996-1999年期间，曾是Neurocrine Biosciences股份有限公司的一位研究助理。他拥有着超过20年的生命科学行业经验。他是在Boston大学获得生物学学士学位、在Santa Barbara市加州大学（University of California）获得生物化学硕士学位，以及在Cornell大学Johnson商学院获得工商管理学硕士学位的。
- Brian M. Culley,joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast's merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast's Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast's Senior Vice President, Business Development, and from 2004 to 2006 as Mast's Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022. Mr. Culley has more than 30 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.